Tear Interleukin Biomarkers After Glaucoma Treatment

ConditionGlaucoma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorKazakh Eye Research Institute

About this trial

This prospective study aims to evaluate inflammatory biomarkers in tear fluid in patients with glaucoma undergoing micropulse transscleral cyclophotocoagulation (MP-CPC), continuous-wave cyclophotocoagulation (CPC), and antiglaucoma surgeries. The study will assess the concentrations of pro- and anti-inflammatory interleukins in tear samples collected before treatment, 5-7 days after the procedure, and 1 month postoperatively.

Intraocular pressure (IOP) will be measured at the same time points. The correlation between changes in interleukin levels and IOP reduction will be analyzed. Additionally, the study aims to compare inflammatory response patterns among the MP-CPC, CPC, and surgical treatment groups and to identify interleukin profiles associated with a clinically significant hypotensive effect.

Eligibility criteria

Qualifiers

Decision to treat by MP-CPC Laser

Patients diagnosed with Glaucoma

Patients aged 18 years old and above

Glaucoma that is inadequately controlled on medical therapy

Disqualifiers

Patients age less than 18 years

Patients unable or unwilling to provide informed consent to participate in the study

Patients potentially unavailable for follow up visits

Patients with significant scleral thinning

Trial design

Treatments tested in this trial

  • MicroPulse Transscleral Cyclophotocoagulation
  • Conventional Transscleral Cyclophotocoagulation
  • Antiglaucoma Surgery

Treatment groups

24 Participants
are divided into 3 treatment groups

Locations

1
Kazakh Eye Research Institute050012, Almaty Kazakhstan

Sponsors and collaborators

Kazakh Eye Research Institute

Lead sponsor